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The Human Genome Organisation (HUGO) was conceived in
1988 at the first meeting on genome mapping and sequencing
at Cold Spring Harbor. Its original purpose was to promote
international collaborative efforts to study the human genome
and to address the myriad issues raised by knowledge of the
genome including ethical and societal questions and issues
around nomenclature. From a 42 scientists of 17 countries
membership association, HUGO has increased its member-
ship base to over 1,200 members from 69 countries.
In 2008, HUGO past its 20th anniversary and decided on a
change in its direction. With the original goal of sequencing
the human genome accomplished, HUGO decided to focus on
two outstanding issues: First,—HUGO will explore the
medical implications of genomic knowledge (i.e., to seek the
biological and medical meaning of genomic information—
genomic medicine); and second, to enhance the genomic
capabilities and to help fulfil the genomic aspirations of the
emerging scientific countries of the world. The excitement and
interest in genomic sciences in Asia, Latin America, the
Middle East, and Africa are palpable and the hope is that these
technologies will help in national development and health.
So it is in these two areas in which HUGO will focus on over
the ensuing years: the expansion of genomic medicine and
greater engagement with the emerging scientific countries:
Genomic medicine
We are at an inflection point of discovery in human genetics.
The confluence of knowledge of the human genome
sequence, the breath-taking advances in genomic technolo-
gies, comparable increases in computational capabilities,
and a maturing knowledge base in systems biology are all
making genome-based medicine a reality. The challenges are
to creative study design to uncover genetic complexity, to
understand how to make clinical decisions based on this
complex genetic information, and to safely and ethically use
the complete genetic information about any individual or
groups of individuals in public health policy. Modularly
deployed and cost effective, high throughput sequencing/
genotyping approaches can be readily established, and
informatics capabilities are accessible and expandable. The
technologies can easily be directed to other non-medical
applications such as in agricultural development, in animal-
live stock management, and in environmental remediation.
So, genomic approaches are effective ways to achieve
competitiveness and impact in biology and medicine over a
short period of time. Many of these issues will be explored in
HUGO’s HGM2010 conference in Montpellier, France, May
17–21, 2010.
All this is new scientific, medical, and social territory.
Whereas the developed nations led these discussions for the
last 40 years, the emerging economies are now asking how
they can integrate this high technology into the fabric of
medical care and of human sustainability. As we bring in
the rest of the world into the discussion, HUGO can be an
important broker of ideas and strategies. Our global reach of
scientific connectivity can be exploited to help humanity.
Science and genomics in the emerging and developing
countries:
In the last 20 years, we all have observed a dramatic
change in the global economic and scientific landscape.
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The emerging economies in India, China, Southeast Asia,
South Africa, South America, Eastern Europe and the
Middle East have risen in economic impact and are putting
these resources into nurturing scientific talent and in
building biomedical research infrastructures. Many gov-
ernments have the desire to exploit genomic technologies
for public health benefits, for capacity building in bio-
medical investigations, in environmental remediation, and
in agricultural advancement.
These emerging and newly developed nations cover over
3 billion of our 6 billion human inhabitants on this earth and
the new talent that can be harnessed to solve medical and
environmental problems is immense. Equally important is
that these countries have strong national memories of the
struggles of being poor developing nations. These experi-
ences, if codified, can be used to help our brethren in
developing countries with little scientific resources.
The HUGO can be an important platform for these
emerging countries to be engaged in global science and
scientific policy. Often considered the UN of genomic sci-
ences, we are often viewed as an unbiased convener of
experts around troublesome issues—as we have in the past
in nomenclature and in bioethics. We can be the trusted
third party in global negotiations, and the wellspring of
expert opinion beholding to no single region or government.
As a reflection of this organisational refocusing, the HUGO
office was moved from London to Singapore, a country that
was founded in 1965 and a recent player in genetics and
genomics.
To extend our connectivity and impact, we have initiated
The HUGO Journal, engaged in social networking in the web
(HUGO Matters), embarked on HUGO sponsored interna-
tional projects (Pan Asian SNP Initiative), and expanded our
conference schedule (http://www.hugo-international.org/).
Going forward, we are excited about our new strategy and
invite all genomic scientists to join us in making an impact.
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